3652 results for «280»
3652 results
Modern risk prediction in TAVI
21 May 2026 – From EuroPCR 2026
This session examines modern risk prediction models in transcatheter aortic valve implantation (TAVI). It presents novel scoring systems, the prognostic significance of cardiac damage extent and progression, and the impact of multivalvular disease, enhancing patient stratification and outcome prediction.
Imaging-guided strategy for understanding coronary calcification
21 May 2026 – From EuroPCR 2026
Focusing on coronary calcification, this session teaches the application of CT and intracoronary imaging to characterize calcium patterns, select appropriate modification tools, and assess procedural success. It emphasizes imaging-guided strategies to optimize treatment of calcified coronary lesions.
New evidence in coronary physiology for microvascular assessment
21 May 2026 – From EuroPCR 2026
This session highlights new evidence in coronary physiology related to microvascular assessment. Topics include endothelial dysfunction in angina with non-obstructive arteries, the prognostic value of microvascular resistance metrics, natural history studies, and trials aimed at standardizing management of microvascular dysfunction.
Imaging evaluation in structural heart interventions
21 May 2026 – From EuroPCR 2026
This session offers a comprehensive evaluation of imaging techniques applied in structural heart interventions. It covers innovative studies including the impact of Dapagliflozin on multivalvular disease post-TAVI, advanced fusion methods combining CT and echocardiography to assess aortic stenosis severity, and the clinical relevance of the fibrocalcific...
Bailout techniques for complications during primary PCI
21 May 2026 – From EuroPCR 2026
This session addresses bailout techniques during primary PCI complications. It covers a range of challenging scenarios such as coronary perforations and complex procedural issues, emphasizing rapid decision-making and effective treatment strategies to improve patient outcomes in high-stakes situations.
New platforms for coronary lesions treatment
21 May 2026 – From EuroPCR 2026
Delve into the latest developments in coronary lesion treatment platforms through this session, highlighting real-world performance data of novel drug-eluting stents like Eternia and Evermine 50. It also presents preclinical insights on biomimetic CD31-coated stents, long-term outcomes of the Fantom BRS platform, and innovative randomized trials...
Identifying and planning protected temporary mechanical circulatory support-based procedures in high-risk patients
21 May 2026 – From EuroPCR 2026
This session provides an in-depth update on protected temporary mechanical circulatory support-based procedures in high-risk cardiac patients. It covers patient identification criteria, device selection, and multidisciplinary planning to optimize outcomes in protected PCI, ventricular ablation, and surgical contexts.
Risk stratification and reperfusion strategies for acute and subacute pulmonary embolism
21 May 2026 – From EuroPCR 2026
Focus on risk stratification and reperfusion strategies for acute and subacute pulmonary embolism through this session. It discusses the impact of elective endovascular therapies in intermediate-high risk patients, intraprocedural complications, and early mortality associated with catheter interventions. Additionally, it reviews real-world outcomes of catheter-directed therapy, national...
Complication management during STEMI intervention: Czech Republic - Greece and Iraq present their cases
21 May 2026 – From EuroPCR 2026
This session presents a critical analysis of procedural strategies in primary PCI for STEMI by exploring complex cases from the Czech Republic, Greece, and Iraq. It delves into mechanisms and management of major PCI complications and highlights the role of emerging novel technologies in primary PCI...
Coronary sinus reducer for microvascular angina
28 Feb 2020
A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...
A randomised, multicenter, non-inferiority comparison of intravascular lithotripsy and super-high-pressure non-compliant balloons for treatment of calcified and refractory coronary lesions - The VICTORY trial
27 Oct 2025
Mirvat Alasnag provides her take on the VICTORY trial presented by Matthias Bossard at TCT 2025 in San Francisco.
Author
The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone versus placebo in patients with myocardial infarction
18 Nov 2024
Mirvat Alasnag provides her take on the CLEAR SYNERGY trial presented by Sanjit S Jolly at AHA 2024 in Chicago.
Author
